Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment
Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...
Bristol Myers Gets Expanded European Approval for Breyanzi
Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.
Investing.com Australia23h
European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy
Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...
Le Lézard23h
Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update
Aadi Bioscience, Inc.  ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, ...
Le Lézard23h
Acarix Named 2025 Digital Innovation Winner by Global Cardiovascular Awards
Acarix, a global leader in AI and acoustics-based cardiac diagnostics, has been awarded the 2025 Digital Innovation Award with an honorable mention for Innovation in Cardiac Imaging at the Global ...
Targeted Oncology20h
Jacobs and Peers Consider Third-Line Treatment in Relapsed/Refractory CLL
During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...
Precision Medicine Online18h
BMS's Breyanzi Gains European Approval as Third-Line Treatment for Follicular Lymphoma
The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.